A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
- Sponsor
- Murdoch Childrens Research Institute
- Study ID
- NCT06383338
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Hodgkin Lymphoma
- Non Hodgkin Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Years - 25 Years
- Healthy Volunteers
- Not accepted
Interventions
- Omeprazole — DRUGSub-therapeutic probe drug administration to measure phenoconversion.
- Dextromethorphan — DRUGSub-therapeutic probe drug administration to measure phenoconversion.
Study Details
PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers. The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications. The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.
Key Dates
- First listed
- Apr 25, 2024
- Start date
- Jul 22, 2025
- Status verified
- Sep 2025
- Primary completion
- Jul 31, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Primary Outcome Measure
Proportion of patients who consent to study and complete baseline and at least two longitudinal timepoints with successful measurement of probe drug MR (Metabolic ratio) [ Time Frame: 12 months, 24 Months ]
Central Contacts
- Rachel Conyers, MBBS (Hons)+61393455522
Related Studies
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)Recruiting · Center for International Blood and Marrow Transplant Research · Birmingham, Alabama
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsPHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin
- Familial Investigations of Childhood Cancer PredispositionRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Auto Stem Cell Transplant for Lymphoma PatientsPHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota